JP7364154B2 - がんを治療するための選択的ｐａｒｐ１阻害剤 - Google Patents

がんを治療するための選択的ｐａｒｐ１阻害剤 Download PDF

Info

Publication number
JP7364154B2
JP7364154B2 JP2020534949A JP2020534949A JP7364154B2 JP 7364154 B2 JP7364154 B2 JP 7364154B2 JP 2020534949 A JP2020534949 A JP 2020534949A JP 2020534949 A JP2020534949 A JP 2020534949A JP 7364154 B2 JP7364154 B2 JP 7364154B2
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
pharmaceutical composition
parp1
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020534949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510677A5 (https=
JP2021510677A (ja
Inventor
メリンダ デュア，
デイヴィッド リード，
ウリアナ バッシュタノヴァ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2021510677A publication Critical patent/JP2021510677A/ja
Publication of JP2021510677A5 publication Critical patent/JP2021510677A5/ja
Application granted granted Critical
Publication of JP7364154B2 publication Critical patent/JP7364154B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020534949A 2018-01-17 2019-01-16 がんを治療するための選択的ｐａｒｐ１阻害剤 Active JP7364154B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1800733.6 2018-01-17
GBGB1800733.6A GB201800733D0 (en) 2018-01-17 2018-01-17 Cancer
PCT/GB2019/050110 WO2019141979A1 (en) 2018-01-17 2019-01-16 Selective parp1 inhibitors to treat cancer

Publications (3)

Publication Number Publication Date
JP2021510677A JP2021510677A (ja) 2021-04-30
JP2021510677A5 JP2021510677A5 (https=) 2021-07-26
JP7364154B2 true JP7364154B2 (ja) 2023-10-18

Family

ID=61256175

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020534949A Active JP7364154B2 (ja) 2018-01-17 2019-01-16 がんを治療するための選択的ｐａｒｐ１阻害剤

Country Status (7)

Country Link
US (1) US20210052632A1 (https=)
EP (1) EP3740238A1 (https=)
JP (1) JP7364154B2 (https=)
CN (1) CN111629757A (https=)
CA (1) CA3087652A1 (https=)
GB (1) GB201800733D0 (https=)
WO (1) WO2019141979A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592555A (en) * 2019-09-27 2021-09-08 Varsity Pharmaceuticals Ltd Cancer
AU2022334408A1 (en) * 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
KR20240149429A (ko) * 2022-02-16 2024-10-14 듀크 스트리트 바이오 리미티드 약학적 화합물
IL317573A (en) * 2022-06-15 2025-02-01 Astrazeneca Ab Combination therapy for cancer treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
US20110190390A1 (en) * 2010-01-05 2011-08-04 Nicole Renee Murray Methods and materials for treating pancreatic cancer
WO2015048718A2 (en) * 2013-09-30 2015-04-02 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Inhibition of thymine dna glycosylase in the treatment of cancer
KR20230075528A (ko) * 2016-05-03 2023-05-31 갈레라 랩스, 엘엘씨 암 치료를 위한 조합 요법
GB2592555A (en) * 2019-09-27 2021-09-08 Varsity Pharmaceuticals Ltd Cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Jacques, A. et al.，Reactivity of Cys4 zinc finger domains with gold(III) complexes: insights into the formation of "gold fingers"，Inorganic Chemistry，2015年，Vol.54, No.8，p.4104-4113，doi:10.1021/acs.inorgchem.5b00360
平沢 晃 ほか，産婦人科臨床における遺伝性乳癌卵巣癌の位置づけ，家族性腫瘍，2011年，第1巻，第2号，p.48-51，doi:10.18976/jsft.11.2_48
竹内 聡, 杉山 徹，固形がん薬物療法における維持療法の最新の知見 進行卵巣がんにおける維持療法 ―分子標的薬の立場より―，癌と化学療法，2014年，第41巻, 第8号，p.937-943

Also Published As

Publication number Publication date
US20210052632A1 (en) 2021-02-25
GB201800733D0 (en) 2018-02-28
WO2019141979A1 (en) 2019-07-25
CN111629757A (zh) 2020-09-04
CA3087652A1 (en) 2019-07-25
JP2021510677A (ja) 2021-04-30
EP3740238A1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
JP7364154B2 (ja) がんを治療するための選択的ｐａｒｐ１阻害剤
JP2021098740A (ja) 悪性病変を処置する方法
US20240066032A1 (en) Methods of treating prostate cancer
US11986469B2 (en) Methods of treating prostate cancer
JP2022009090A (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
US20210000824A1 (en) Intermittent dosing of mdm2 inhibitor
CN103635187B (zh) 用于抑制化疗引起的副作用的药物治疗以及相关药物组合物、诊断试剂、筛选技术和试剂盒
US8507555B2 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2019074116A1 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
EA020624B1 (ru) Кристаллическая полиморфная форма n-(-)-(3,4-дифтор-2-(2-фтор-4-йодфениламино)-6-метоксифенил)-l-(2,3-дигидроксипропил)циклопропан-1-сульфонамида и ее применение в качестве ингибитора mek
EA030808B1 (ru) ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
JP6147246B2 (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
RU2558835C2 (ru) Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2
TW202320792A (zh) 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
JP2022500497A (ja) がん治療で用いる５−アセトアミドメチルオキサゾリジノン誘導体
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
US20220000911A1 (en) Combination of gold complexes with olaparib or other parp1/2 inhibitors for use in the treatment of cancer resistant to said parp1/2 inhibitors
US11198675B2 (en) DNA2 inhibitors for cancer treatment
US20110190400A1 (en) Novel Compounds for Treatment of Malignant Tumors
KR20220035379A (ko) 암 치료를 위한 조합 요법
US20240366540A1 (en) Mitofusin inhibitors and uses thereof
Padrón Carrillo et al. Click-chemistry mediated synthesis of OTBN-1, 2, 3-Triazole derivatives exhibiting STK33 inhibition with diverse anti-cancer activities
WO2023107880A1 (en) Mitofusin inhibitors and uses thereof
KR20230030328A (ko) 뇌종양의 치료용 약학적 조성물
HK40029376B (en) Drug therapy to inhibit chemotherapy-induced adverse effects and screening techniques and kits

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230922

R150 Certificate of patent or registration of utility model

Ref document number: 7364154

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150